An Array Of Great Points For Marketing Niche Products

Surely, the pharmaceutical market is one of the most interesting and diverse industries, always in a state of change and flux, but in more recent times, we can see a distinct trend away from big brand product, wide reach styles of marketing toward a focus on the “niche” medicines; this process also seems to be accelerating. This poses an additional challenge for the pharmaceutical company’s sales staff, especially in the arena of professional education.

All-important product branding must now be determined at a very early stage of the development cycle and pharmaceutical companies must be even more aware of how volatile the market can be and how constraints can emerge as the company seeks to enter, penetrate and extend into niche markets, which are often more focused and narrow minded. It is possible that resistance could be significant and this can mean that more attention should be paid to branding as a critical early component of the marketing cycle.

Now more than ever, pharmaceutical markets are crowded. The consumer has a wide array of choices and is increasingly more influenced by a variety of external forces in addition to the direct advice that may be given to them by the professional or practitioner. Every one of us expects instantaneous information to be available whenever we need it and we’re now getting used to engaging with each other much more often within social networks and online. As a consequence, we are becoming much more educated about every aspect of our existence. While the consumer becomes more educated and the market becomes more crowded, the efficiency of a marketing program must be in sharp focus for a company’s senior executives.

Pharmaceutical companies are spending a great deal of their time moulding and shaping the market so that it is ready for the product when it is released. This underlines the need for early marketing efforts during brand creation and the need to ensure that educational channels are engaged.

While niche product areas are the subject of greater marketing emphasis, more emotions are involved in the end-user decision process as well and the professional is less likely to advise the consumer to go down the more beaten track. This requires a pharmaceutical company to be very clear and distinct in its marketing methods and messages, in order to differentiate itself from its competitors in the eyes of its target markets. This clearly puts pressure on the company’s sales force as these executives must now try and penetrate a sceptical barrier at the professional level and ensure that the message is stronger, yet more targeted than before.

The sales force is of primary importance to the success of the company and senior officials are turning in greater numbers to pharmaceutical consultants and pharmaceutical consulting firms to help them train and focus the force accordingly. In most cases, pharma consulting plays a great role in helping the organisation to identify shifting marketing forces, especially when associated with niche concentration. The distant professional must be the subject of more attention and sharper skills will be needed, with more training required to ensure that the sales executive breaks through all barriers and achieves the results. Effective implementation requires an equal amount of experience, ability and training.

Alan Gillies is the Director of L2L Consulting, an elite pharmaceutical consultancy firm which specialises in Strategy Development and Implementation Excellence for prestigious multi-national organisations.